Solve Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies for cancer with high unmet need. Its pipeline includes highly selective antibody-drug conjugates (ADCs) enabled by its proprietary CloakLink™ hydrophilic linker technology.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.11.2025 | - | $120M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.11.2025 | Solve Therapeutics Raises $120 M in Upsized Funding | Solve Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumor malignancies, raised $120m in an upsized financing.
The round was led by Yosemite, with participation ... |
| 14.12.2022 | Solve Therapeutics Announces Mission to Advance Novel Antibody-Based Therapies Against Cancer-Specific Targets | Venture-backed biopharmaceutical company headquartered in San Diego and led by veteran drug developers with strong track records of success Pursuing novel antibody-based therapeutics, including monoclonal antibodies (mAbs), antibody-drug co... |
| - | Solve Therapeutics | “Targeting cancer with best-in-class ADCs Solve is developing novel antibody-drug conjugates (ADCs) with high selectivity and optimized payload delivery enabled by CloakLink™, our proprietary hydrophilic linker system. Science Realizing the... |
Reviews 0
